Pharma-Bio Serv, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $9.5M | $17.0M | $19.4M | $20.1M | $21.6M | $19.5M | $17.8M |
| Cost of Revenue | $6.1M | $7.0M | $11.9M | $14.5M | $14.8M | $14.9M | $13.3M | $12.1M |
| Gross Profit | $2.9M | $2.5M | $5.1M | $4.9M | $5.4M | $6.7M | $6.2M | $5.7M |
| Gross Margin | 32.3% | 26.5% | 29.8% | 25.2% | 26.6% | 30.9% | 31.7% | 32.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.5M | $3.8M | $3.9M | $3.7M | $9.2M | $4.4M | $4.5M | $4.6M |
| Operating Income | $-637.7K | $-1.3M | $1.1M | $1.2M | $-3.9M | $2.2M | $1.7M | $-1.3M |
| Operating Margin | -7.1% | -13.5% | 6.6% | 6.1% | -19.2% | 10.3% | 8.7% | -7.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-94.3K | $-755.4K | $1.7M | $1.2M | $-1.9M | $2.3M | $2.2M | $1.5M |
| Income Tax Expense | $6.2K | $22.2K | $377.3K | $181.7K | $213.2K | $239.1K | $136.0K | $2.8M |
| Net Income | $-100.5K | $-777.6K | $1.3M | $1.0M | $-2.1M | $2.1M | $2.1M | $1.3M |
| Net Margin | -1.1% | -8.2% | 7.7% | 5.2% | -10.4% | 9.5% | 10.7% | 7.2% |
| EPS (Basic) | — | — | — | — | — | $0.09 | $0.09 | — |
| EPS (Diluted) | $0.00 | $-0.03 | $0.06 | — | — | $0.09 | $0.09 | — |
| Shares Outstanding (Basic) | 22.9M | 23.0M | 23.0M | 23.0M | 23.0M | 23.0M | 23.1M | 23.1M |
| Shares Outstanding (Diluted) | 23.0M | 23.0M | 23.0M | 23.0M | 23.2M | 23.0M | 23.1M | 23.1M |
| Dividends Per Share | — | — | — | — | — | — | $0.08 | — |